Showing results (611-620 of 1,030) with videos related to

Sort By:
Pageof 103
The Lancet. Respiratory Medicine|May 6, 2014
Asthma genetics and personalised medicineDeborah A Meyers, Eugene R Bleecker, John W Holloway, et al.
The Lancet. Respiratory Medicine|April 11, 2014
Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trialAndrew R Goudie, Brian J Lipworth, Pippa J Hopkinson, et al.
The Lancet. Respiratory Medicine|April 11, 2014
Progress in tuberculosis vaccine development and host-directed therapies--a state of the art reviewStefan H E Kaufmann, Christoph Lange, Martin Rao, et al.
The Lancet. Respiratory Medicine|April 11, 2014
Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort studyAndrew C Hayward, Ellen B Fragaszy, Alison Bermingham, et al.
The Lancet. Respiratory Medicine|April 11, 2014
Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trialPallavi Mandal, James D Chalmers, Catriona Graham, et al.
The Lancet. Respiratory Medicine|April 29, 2014
Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET studyMeiLan K Han, Yueren Zhou, Susan Murray, et al.
The Lancet. Respiratory Medicine|May 13, 2014
Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort studyJames C Jackson, Pratik P Pandharipande, Timothy D Girard, et al.
The Lancet. Respiratory Medicine|September 12, 2014
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a studyChristopher E Brightling, Eugene R Bleecker, Reynold A Panettieri, et al.
The Lancet. Respiratory Medicine|September 14, 2014
Radiological correlates and clinical implications of the paradoxical lung function response to β₂ agonists: an observational studySurya P Bhatt, James M Wells, Victor Kim, et al.
The Lancet. Respiratory Medicine|October 15, 2014
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)Edward F McKone, Drucy Borowitz, Pavel Drevinek, et al.
Pageof 103